All Janssen articles
-
BusinessPfizer–BioNTech vaccine gains emergency approvals in US, Canada and beyond
UK begins vaccinating vulnerable populations after early authorisation
-
BusinessEncouraging signs from initial Covid-19 vaccine trials
Human trials deliver positive immune responses, while primate challenge studies suggest protection is possible
-
-
BusinessUS to invest $160m in cancer partnership
Funds will be backed up with $55m from 11 companies to advance new cancer treatments that harness the immune system
-
BusinessLong road to recovery for Puerto Rico pharmaceuticals
As inhabitants begin to rebuild their lives after the devastation of hurricane Maria, the island’s drug manufacturers are recovering slowly
-
BusinessAmgen partners to launch biosimilars in China
US biopharma and Chinese generics firm will co-develop medicines from Amgen’s pipeline focused on inflammation and oncology
-
BusinessUS probes opioid manufacturers
Attorneys general from 41 states will investigate companies over alleged fraudulent marketing and distribution of painkillers
-
BusinessJ&J licenses Protagonist’s inflammatory bowel peptide
Potential first-in-class treatment is just about to enter clinical trials
-
BusinessJ&J to buy Actelion for $30bn
Actelion’s R&D will spin out as a new company, while Janssen will take on in-market and late-stage medicines
-
BusinessAmgen and Advaxis partner on immuno-oncology
Deal covers rights to system for building cancer therapies specific to a patient’s own tumours
-
Business
Achillion partners with Janssen to boost hepatitis C pipeline
Development deal worth up to $1.1bn includes three investigational drugs aiming to extend treatment options in fast-moving market
-
BusinessAbbVie to buy Pharmacyclics for pipeline boost
$21bn deal gives AbbVie a share in sales of blockbuster cancer drug as its own biggest sellers face patent expiry
-
-
Business
Illumina targets cancer diagnostics
Sequencing will improve tests and speed up clinical trials processes for big pharma partners
-
Business
$1.2bn J&J deceptive marketing fine overturned
Supreme court reverses decision to fine firm over Risperdal promotion
-
FeatureThe hunt for innovation
Big pharma companies are embracing a more open and collaborative approach. Nuala Moran discovers who’s working with whom
-
BusinessMis-selling lands J&J with $2.2bn fine
Company found guilty of promoting three drugs for unapproved uses
-
Business
TB drug milestone for bedaquiline
First TB drug with a new mechanism of action for 40 years wins approval
-
Business
Elan spins off drug discovery
The new company will be called Neotope Biosciences and focus on chronic degenerative diseases
-
News€224 million EU antibiotics initiative launched
The project will bring together the pharmaceutical industry and academia, but some institutes have reservations